Bevacizumab news

All news on Bevacizumab (also known as Avastin): plants, production capacities, investments and involved companies.

10 June 2026

Genentech: FDA grants Priority Review for Tecentriq plus chemotherapy in stage III dMMR/MSI‑H colon cancer

FDA accepted an sBLA for adjuvant PD‑L1 therapy plus chemotherapy in stage III dMMR/MSI‑H colon cancer; agency decision expected Oct 9, 2026.
30 April 2026

Merck & Co Q1 2026 Results — Sales Growth, Regulatory Approvals and Clinical Milestones

Q1 revenue $16.3B; KEYTRUDA $8.0B. GAAP loss $1.72/sh, non-GAAP loss $1.28/sh after $9.0B Cidara charge. Announced Terns acquisition; raised 2026 sales to $65.8-67.0B and non-GAAP EPS $5.04-5.16
27 February 2026

Merck's KEYTRUDA Plus Paclitaxel Boosts Survival in Platinum-Resistant Ovarian Cancer

KEYTRUDA plus paclitaxel improves overall survival in platinum-resistant ovarian cancer, regardless of PD-L1 status, as shown in the KEYNOTE-B96 trial.
11 February 2026

Merck's KEYTRUDA and KEYTRUDA QLEX Approved for PD-L1+ Platinum-Resistant Ovarian Cancer

FDA approves KEYTRUDA regimens for platinum-resistant ovarian cancer, showing reduced disease progression and death risk in trials.
20 January 2026

Lilly's Sofetabart Mipitecan Gains FDA Breakthrough Status for Platinum-Resistant Ovarian Cancer

FDA grants Breakthrough Therapy status to sofetabart mipitecan for platinum-resistant ovarian cancer, based on promising Phase 1 results. Phase 3 trial underway.
19 October 2025

Raludotatug Deruxtecan Shows 50.5% Response in Platinum-Resistant Ovarian Cancer, Reports Daiichi Sankyo and Merck

Raludotatug deruxtecan achieved a 50.5% response rate in phase 2 for platinum-resistant ovarian cancer, with a 5.6 mg/kg dose selected for phase 3.

Who will be producing Bevacizumab in the future?

Find out with chemXplore Alpha

Learn more